Acadia calls early halt to Nuplazid psychosis trial after promising interim results
admin 10th September 2019 Uncategorised 0Acadia was stung hard after its schizophrenia hopes for flagship Nuplazid fell flat back in late July. On the heels of that failure, Acadia is calling off a trial in dementia-related psychosis after it saw promising interim results for the drug.
More: Acadia calls early halt to Nuplazid psychosis trial after promising interim results
Source: fierce